Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 06-DA-N409 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
- Many cigarette smokers claim that smoking helps them stay alert and improves their concentration, and have reported problems in attention and concentration after quitting smoking. Some research has indicated that nicotine can enhance certain aspects of attention and memory in humans. However, more research is needed to determine how nicotine affects different elements of the brain's ability to pay attention. Knowing which aspects of attention are affected by nicotine may help produce new medications and therapies to help people successfully stop smoking.
Objectives:
Eligibility:
- Individuals between 18 and 50 years of age who are either current smokers (at least 15 cigarettes per day on average for at least 2 years) or healthy, nonsmoking volunteers.
Design:
Objective: The primary objective of this study is to investigate the dose-related effects of nicotine on various elements of attention in smokers and nonsmokers. Because no published study, to our knowledge, has reported the effects of nicotine on the ANT and ABT, we will include the CPT, a task shown to be sensitive to nicotine, as a positive control. A secondary aim is to compare the subjective and physiological effects of nicotine between smokers and nonsmokers.
Study Population: 50 smokers for a total of 30 completers (15 women, 15 men) and up to 50 nonsmokers for a total of 30 completers (15 women, 15 men).
Design: Placebo-controlled, between-groups comparison of smokers and nonsmokers. Participants will attend three experiemental sessions; a single dose of nicotine nasal spray (0, 0.5, or 1.5 mg) will be administered at each session.
Outcome Measures: Primary outcome measures will be accuracy and/or response time on the three attention tests, ANT, CPT, and ABT. Secondary outcome measures include responses to the PANAS, VAS items, and vital signs (heart rate and blood pressure). Participant demographics and smoking history will be reported using descriptive statistics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotine | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacodynamics, changes in cognitive function |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in subjective mood, changes in cardiovascular measures |
Not provided
INCLUSION CRITERIA: Smokers
be men and women 18-50 years old
report smoking at least 15 cigarettes per day on average for at least 2 years
have a urine cotinine level greater than or equl to 200 ng/ml
have an estimated IQ score greater than or equal to 85
be medically and psychologically healthy as determined by screening criteria
EXCLUSION CRITERIA: Smokers
4) report consumption of more than 15 alcoholic drinks per week during the past month
5) report use of marijuana more than once per week during the past month
6) report use of any illicit drug, other than marijuana, during the past 6 months
7) be currently using any medication that would interfere with the protocol
8) be under the influence of a drug or alcohol at experimental sessions
9) be pregnant or nursing
10) be HIV positive.
INCLUSION CRITERIA: Nonsmokers
EXCLUSION CRITERIA: Nonsmokers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institute on Drug Abuse, Biomedical Research Center (BRC) | Baltimore | Maryland | 21224 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 11044746 | Background | Bancroft A, Levin ED. Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology. 2000 Oct;39(13):2770-8. doi: 10.1016/s0028-3908(00)00099-x. | |
| 8453850 | Background | Benowitz NL, Jacob P 3rd. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther. 1993 Mar;53(3):316-23. doi: 10.1038/clpt.1993.27. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D014029 | Tobacco Use Disorder |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D009538 | Nicotine |
| ID | Term |
|---|---|
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 15187577 | Background | Bizarro L, Patel S, Murtagh C, Stolerman IP. Differential effects of psychomotor stimulants on attentional performance in rats: nicotine, amphetamine, caffeine and methylphenidate. Behav Pharmacol. 2004 May;15(3):195-206. |
| D006573 |
| Heterocyclic Compounds, 1-Ring |